|
|
Giuseppe Destito
destito@scripps.edu
Pratik Singh, Ph.D
prasingh@scripps.edu
Kris Koudelka
koudelka@scripps.edu
Mayra Estrada
evilgirl@scripps.edu
Tumor targeting using VNPs
We have designed VNPs that can specifically target tumors in vivo. In collaboration with M.G. Finn, Department of Chemistry, CPMV was bioconjugated to tumor ligands such as transferrin and folic acid, whose receptors are upregulated on metabolically active tumor cells. The targeted particles showed a high degree of specificity for the tumor ligand and uptake in tumor cells. In a separate study, we showed that the canine parvovirus (CPV), which has a natural affinity for transferrin receptor and thus for tumor cells, was able to specifically deliver small molecules to tumor cells. These studies will allow the further design of anti-tumor agents that can provide localized, highly specific imaging and therapy in vivo. The potential exists for VNPs to help visualize and eliminate small tumors before they have a chance to metastasize. In addition, the ability of VNPs to focus toxic effects to the site of the malignant cells, thereby expanding the range of effective therapies that can be used in vivo, holds great promise for reducing cancer-related morbidity and mortality.
Home Page · Research · Contact
Publications · Members Only
· TRSI Home Page
|
|
|